Impact of type 2 diabetes mellitus on short-term and long-term outcomes of patients with esophageal squamous cell cancer undergoing resection: a propensity score analysis

Wang Yao1,2†, Yuqi Meng1,3†, Mingjian Lu1,4, Wenzhe Fan2, Jinhua Huang1, Jiaping Li2* and Zhihua Zhu1*

Abstract
Background: The association between type 2 diabetes mellitus (T2DM) and the risk of esophageal cancer remains unclear. The present study aimed to evaluate the impact of T2DM on short-term outcomes and long-term survival in patients with esophageal squamous cell cancer (ESCC).

Methods: The present retrospective study included 862 patients diagnosed with ESCC between January 2001 and December 2010. Among them, 280 patients had T2DM. A 1:1 propensity score-matched cohort consisting of 280 patients with and 280 without T2DM was selected from the 862 patients. The associations between T2DM and clinico-pathologic characteristics were assessed using the χ² or Fisher's exact test. Survival of ESCC patients with and without T2DM was calculated by using the Kaplan–Meier method and compared by using the Cox regression model between the two groups.

Results: The occurrence rate of anastomotic leakage was significantly higher in patients with T2DM than in those without T2DM (P < 0.001). In the subgroup with weight loss rate ≤ 5.05%, ESCC patients with T2DM had a significant longer overall survival than did those without T2DM (P = 0.003), whereas in the subgroup with weight loss rate > 5.05%, the patients without T2DM showed a longer survival (P = 0.001). Univariate and multivariate analysis results showed that T2DM was not an independent prognostic factor for patient survival.

Conclusions: Type 2 diabetes mellitus is not an independent prognostic factor in patients with ESCC. However, the combination of T2DM with severe weight loss would be a predictor of poor prognosis.

Keywords: Type 2 diabetes mellitus, Esophageal cancer, Prognosis, Overall survival
Background

Esophageal cancer is the fifth most common cancer in China, with 287,600 patients newly diagnosed each year, and the fourth most frequent cause of cancer-related deaths, accounting for 210,900 deaths each year [1]. In Asian countries, more than 90% of esophageal cancers are esophageal squamous cell carcinomas (ESCC) [2]. Surgery remains the predominant modality in the management of esophageal cancer [3].

Over the past two decades, the markedly increased morbidity of type 2 diabetes mellitus (T2DM) in most countries has suggested a possible association between diabetes mellitus and cancer [4]. T2DM patients have shown an increased incidence of several cancers, including pancreatic cancer [5], liver cancer [6, 7], colorectal cancer [8], gastric cancer [9], and renal cancer [10]. In contrast, a decreased incidence of prostate cancer has been observed in diabetic patients, suggesting a protective effect of diabetes [11]. However, the effect of T2DM on the prognosis of patients with several types of cancer, including lung cancer, remains unclear [12, 13].

Over the past two decades, the association between T2DM and the risk of esophageal cancer has been examined in different population- and hospital-based settings, but these studies have yielded inconsistent results [14, 15]. A recent meta-analysis reported by Huang et al. [16] has supported the hypothesis that men with diabetes may have a modestly increased risk of esophageal cancer. To date, however, the prognostic significance of T2DM in ESCC has not yet been determined. In the present study, we therefore evaluated the effect of T2DM on the prognosis of ESCC patients who underwent curative surgery.

Patients and methods

Study design

The study included patients with histologically proven ESCC who underwent conventional open esophagectomy with 2-field lymphadenectomy at the First Affiliated Hospital of Sun Yat-sen University, the Second Hospital of Lanzhou University, or Sun Yat-sen University Cancer Center between January 2001 and December 2010. Patients were excluded if they (1) had received preoperative or/and postoperative chemotherapy and/or radiotherapy; (2) presented with synchronous primary tumors and/or had previous malignant diseases; (3) underwent R1 or R2 resection; or (4) underwent subtotal/total gastrectomy or had other complications, including hypothyroidism or active tuberculosis.

A diagnosis of diabetes mellitus is based on a patient’s history of diabetes mellitus and/or the use of antidiabetic medications in the hospital medical record (all diabetes diagnoses should be made on the basis of classification and diagnosis of Diabetes released in 2015) [17]. Blood sugar levels were rigorously controlled by insulin injections during the perioperative period.

To minimize the effect of potential confounders on selection bias, propensity score-matching analysis was performed. Factors related to combined treatment were entered into the propensity model; these factors included age, sex, smoking status, drinking status, weight loss rate, body mass index (BMI), tumor location, tumor grade, pT category, pN category, pathological tumor/node/metastasis (pTNM) stage, and complications. Patients with and without T2DM were matched one-to-one using the optimal matching method. The adjusted comparisons by propensity scores were based on data from the patients with T2DM. After adjustment for these factors, overall survival (OS) rates, baseline characteristics, and were reanalyzed to explore the prognostic factors for the patients with and without T2DM.

Preoperative evaluation included a complete history, a physical examination, complete blood cell counts, serum biochemistry, chest X-rays, barium swallow test, computed tomography (CT) scans of the chest and abdomen, ultrasonic esophagscopy, and mandatory cardio-pulmonary assessments.

Follow-up

Postoperative follow-up and CT scans were performed every 3 months during the first year, every 6 months during the next 2 years, and once every year thereafter. Contrast CT scans of the lower neck, thorax, and upper abdomen, including the liver and adrenal glands, were routinely performed.

Survival status was verified using the best available methods in December 2015, including reviews of outpatient records and direct telecommunication with each patient or his/her family. T2DM history, weight loss, BMI, smoking status, and drinking status were determined by reviewing each patient’s medical records at the first visit to a hospital. Weight loss rate was defined as the following formula [18]:

$$\text{Weight loss rate} = \frac{\text{weight1} - \text{weight2}}{\text{weight1}}$$

weight1: body weight measured on the first day of admission.
weight2: body weight measured before leaving the hospital.

Because few reports have defined weight loss rate, this parameter was empirically divided into four categories: 0, > 0 to ≤ 5%, > 5% to ≤ 10%, and > 10%.

Complications were estimated from clinical, laboratory, and imaging data. The pTNM stage of each patient was defined according to the criteria of the American Joint Committee on Cancer staging system (2010).
Statistical analysis
All statistical analyses were performed using the SPSS 19.0 software package (IBM, Chicago, IL, USA). OS was defined as the time from the date of surgery to the date of death or final clinical follow-up. All patients lost to follow-up or being alive at the last follow-up were censored. Associations between T2DM and clinicopathologic characteristics were assessed using the χ² or Fisher’s exact test. Survival rates were calculated with Kaplan–Meier curves and compared with log-rank tests. Univariate and multivariate cox regression analyses were controlled for the variables mentioned above. A two-sided P value < 0.05 was considered statistically significant. Receiver operating characteristic (ROC) curve was constructed using Medcalc 12.0 (Medcalc Company, Brussels, Belgium). Propensity score-matched analysis was performed using R software (TIBCO, Silicon Valley, CA, USA).

Results
Patient characteristics
Between January 2001 and December 2010, a total of 2489 patients with ESCC underwent open esophagectomy at the three institutions. The study cohort consisted of 862 patients with ESCC who underwent surgery as primary therapy; 638 (74.0%) of them were male (Fig. 1). Before propensity score matching, the mean age of all patients was 60.1 ± 9.2 years. The median weight loss rate and BMI of these patients were 0.0% (range, 0–18.8%) and 22.06 kg/m² (range, 14.98–32.96 kg/m²), respectively.

Excluded (n = 1627)
Other carcinoma history (n = 49)
Other adjuvant therapy (n = 1313)
Missing data (n = 82)
With R1 or R2 resection (n = 52)
Accompanied with gastrectomy or declined (n = 131)

Between January 2001 and December 2010, 2489 ESCC patients underwent esophagectomy

280 ESCC patients with T2DM
582 ESCC patients without T2DM

Matching process (1:1)
The factors include: age, sex, smoke, drink, weight loss rate, BMI, tumor location, tumor grade, pT, pN, pTNM and complication

n = 280
n = 280

Fig. 1 The flow diagram of patient selection. ESCC esophageal squamous cell cancer, T2DM type 2 diabetes mellitus, pT pathological tumor, pN pathological node, pTNM pathological tumor/node/metastasis, BMI body mass index
| Characteristic                  | Before matching | P value<sup>a</sup> | After matching | P value<sup>a</sup> |
|-------------------------------|-----------------|---------------------|----------------|---------------------|
| No. of cases (%)              | With T2DM (%)   | Without T2DM (%)    | With T2DM (%)  | Without T2DM (%)    |
| Age (years)                   |                 |                     |                |                     |
| ≤ 45                          | 48 (5.6)        | 4 (1.4)             | 13 (2.3)       | 9 (3.2)             |
| 46–59                         | 370 (42.9)      | 112 (40.0)          | 225 (40.2)     | 113 (40.4)          |
| ≥ 60                          | 444 (51.5)      | 164 (58.6)          | 322 (57.5)     | 158 (56.4)          |
| Sex                           |                 |                     |                |                     |
| Female                        | 224 (26.0)      | 92 (32.9)           | 195 (34.8)     | 103 (36.8)          |
| Male                          | 638 (74.0)      | 188 (67.1)          | 365 (65.2)     | 177 (63.2)          |
| Smoking status                |                 |                     |                |                     |
| Yes                           | 362 (42.0)      | 160 (57.1)          | 317 (56.6)     | 157 (56.1)          |
| No                            | 500 (58.0)      | 208 (74.3)          | 243 (43.4)     | 123 (43.9)          |
| Drinking status               |                 |                     |                |                     |
| Yes                           | 638 (74.0)      | 224 (80.0)          | 445 (79.5)     | 221 (78.9)          |
| No                            | 224 (26.0)      | 56 (20.0)           | 115 (20.5)     | 59 (21.1)           |
| Weight loss rate              |                 |                     |                |                     |
| 0                             | 474 (55.0)      | 144 (51.4)          | 292 (52.1)     | 148 (52.9)          |
| > 0% to ≤ 5%                  | 152 (17.6)      | 56 (20.0)           | 102 (36.4)     | 46 (16.4)           |
| > 5% to ≤ 10%                 | 182 (21.1)      | 40 (14.6)           | 126 (22.5)     | 66 (23.6)           |
| > 10%                         | 54 (6.3)        | 20 (7.2)            | 40 (7.1)       | 20 (7.1)            |
| BMI (kg/m²)                   |                 |                     |                |                     |
| < 18.5                        | 76 (8.8)        | 8 (2.9)             | 34 (6.0)       | 26 (9.3)            |
| ≥ 18.5 to < 25.0              | 622 (72.2)      | 208 (74.3)          | 393 (70.2)     | 185 (66.1)          |
| ≥ 25.0                        | 164 (19.0)      | 64 (22.8)           | 133 (23.8)     | 69 (24.6)           |
| Tumor location                |                 |                     |                |                     |
| Upper                         | 58 (6.7)        | 20 (7.1)            | 34 (6.0)       | 14 (5.0)            |
| Middle                        | 560 (65.0)      | 160 (57.2)          | 337 (60.2)     | 177 (63.2)          |
| Lower                         | 244 (28.3)      | 100 (35.7)          | 189 (33.8)     | 89 (31.8)           |
| Tumor grade                   |                 |                     |                |                     |
| G1                            | 232 (26.9)      | 80 (28.6)           | 148 (26.4)     | 68 (24.3)           |
| G2                            | 386 (44.8)      | 120 (42.8)          | 264 (47.2)     | 144 (51.4)          |
| G3                            | 244 (28.3)      | 80 (28.6)           | 148 (26.4)     | 68 (24.3)           |
| pT category                   |                 |                     |                |                     |
| T1                            | 48 (5.6)        | 8 (2.9)             | 18 (3.2)       | 10 (3.6)            |
| T2                            | 232 (26.9)      | 76 (27.1)           | 163 (29.1)     | 87 (31.1)           |
| T3                            | 582 (67.5)      | 196 (70.0)          | 379 (67.7)     | 183 (65.3)          |
| pN category                   |                 |                     |                |                     |
| N0                            | 476 (55.2)      | 144 (51.4)          | 285 (50.9)     | 141 (50.4)          |
| N1                            | 242 (28.1)      | 80 (28.6)           | 172 (30.7)     | 92 (32.8)           |
| N2                            | 124 (14.4)      | 52 (18.6)           | 96 (17.1)      | 44 (15.7)           |
| N3                            | 20 (2.3)        | 4 (1.4)             | 7 (1.3)        | 3 (1.1)             |
| pTNM stage                    |                 |                     |                |                     |
| Stage I                       | 46 (5.3)        | 8 (2.9)             | 20 (3.6)       | 12 (4.3)            |
| Stage II                      | 450 (52.2)      | 140 (50.0)          | 273 (48.7)     | 133 (47.5)          |
| Stage III                     | 366 (42.5)      | 132 (47.1)          | 267 (47.7)     | 135 (48.2)          |
| Complication                  |                 |                     |                |                     |
| None                          | 718 (83.3)      | 216 (77.1)          | 458 (81.8)     | 242 (86.4)          |
| Anastomotic leakage           | 82 (9.5)        | 48 (17.1)           | 60 (10.7)      | 12 (4.3)            |
| Pneumonia                     | 32 (3.7)        | 8 (2.9)             | 22 (3.9)       | 14 (5.0)            |
After propensity score matching, mean age was 61.8 ± 9.0 years, the median weight loss rate was 3.1% (range, 0–18.8%), and the median BMI was 22.75 kg/m² (range, 14.98–32.96 kg/m²). The characteristics of the 280 matched T2DM and non-T2DM patients are shown in Table 1. All further statistical analyses were performed on this population.

Patient characteristics by T2DM
Of the 862 patients, 280 (32.5%) had T2DM and 582 (67.5%) did not. These two groups were well matched in weight loss rate, tumor location, tumor grade, pT category, pN category, and pTNM stage. However, the patients with T2DM were significantly older ($P = 0.012$), had higher percentage of smoking ($P < 0.001$), had a significantly higher percentage of female ($P = 0.024$), had a significantly higher BMI ($P = 0.006$), had significantly higher probability of no complications ($P = 0.018$), and had higher rates of postoperative anastomotic leakage ($P = 0.001$) than the patients without T2DM. After propensity score matching, all characteristics in the two groups were well matched, except for the probability of no complication ($P = 0.004$) and postoperative anastomotic leak ($P < 0.001$) (Table 1).

Overall survival and T2DM
The median and mean OS were 45.5 and 39.0 months, respectively. The 1-, 3-, and 5-year OS rates for the entire patient cohort were 86.6%, 53.2%, and 30.2%, respectively (Fig. 2a). Log-rank test showed that the OS rate tended to be higher in ESCC patients with T2DM than in those without T2DM, but the difference between them was not significant ($P = 0.563$, Fig. 2b).

The modeled area under curve (AUC) for weight loss rate was 0.593 ($P < 0.001$, 95% confidence interval [CI] 0.551–0.634; Fig. 3). The diagnostic value of the weight loss rate was significantly associated with AUC, with the cutoff points for weight loss rate being 5.05%; the sensitivity and specificity of cutoff points were 0.616 and 0.595, respectively.

Subgroup analysis of patients with low weight loss rate ($\leq 5.05\%$) showed that survival was significantly longer in patients with T2DM than in those without T2DM ($P = 0.003$, Fig. 4a). In contrast, analysis of patients with
high weight loss rate (>5.05%) showed that survival was significantly shorter in patient with T2DM than in those without T2DM ($P=0.001$, Fig. 4b).

### Univariate and multivariable analyses

Univariate analysis showed that T2DM was not significantly associated with patient survival. In contrast, sex (hazard ratio [HR] 0.769; $P=0.030$), weight loss rate (HR 1.168; $P=0.005$), tumor grade (HR 1.489; $P<0.001$), pT category (HR 1.642; $P<0.001$), pN category (HR 1.820; $P<0.001$), and pTNM stage (HR 2.270; $P<0.001$) were significantly associated with the survival of patients with ESCC (Table 2). In multivariate analysis, only tumor grade (HR 1.373; $P<0.001$) and pN category (HR 1.474; $P=0.001$) were significantly associated with patient survival (Table 2).

### Discussion

The present study found no significant difference in OS between the ESCC patients with T2DM and those without T2DM. Analysis of the subgroup of patients with weight loss rate $\leq 5.05\%$ showed that OS was significantly longer in patients with T2DM than in those without T2DM, whereas analysis of the subgroup with weight loss rate $>5.05\%$ showed that OS was significantly shorter in patients with T2DM than in those without T2DM.

Although the underlying impact of T2DM on ESCC prognosis is unclear, several possible mechanisms have been proposed. Metabolic abnormalities associated with diabetes, such as insulin resistance, compensatory hyperinsulinemia, and elevated levels of bioactive insulin-like growth factor and/or chronic inflammation, can stimulate cancer cell mitogenesis, proliferation, invasion, and metastasis, enhancing tumorigenesis and progression [19]. Hyperinsulinemia has been shown to increase bioavailable estrogen and testosterone [20], sex hormones that play a role in the development of ESCC [21]. In addition, early evidence suggests that some treatments of diabetes may affect cancer risk [19]. For example, exposure to metformin was reported to be significantly associated with prolonged survival in patients with various types of cancer, including thyroid cancer [22], colorectal cancer [23], laryngeal squamous cell cancer [24], melanoma [25], and pancreatic cancer [26]. Delayed gastric emptying is frequent in patients with diabetes, increasing the likelihood of gastric/esophageal reflux, a risk factor for ESCC [27–29]. However, the association between T2DM and ESCC remains complicated and ambiguous, including a need for additional studies.

The present study showed that T2DM was associated with several clinical factors of patients with ESCC. In accordance with the previous studies [30, 31], we found that T2DM was more likely to occur in older patients,
women, patients with a history of smoking, and patients with a high BMI. Our findings also demonstrated that the rate of anastomotic leakage was almost threefold higher in patients with T2DM than in those without T2DM. One of the adverse consequences of hyperglycemia is wound healing delay, which may lead to anastomotic leakage [31].

Interestingly, survival benefits seen in patients with T2DM have been reported to depend on more frequent and regular consultations, resulting in an earlier diagnosis [11]. However, because of the drawbacks of our clinical follow-up data, we could not compare the frequencies of consultations between the two groups of patients.

Despite the potential contributions of T2DM to survival benefits in patients with ESCC, the effect of T2DM on metabolism cannot be ignored. Nutritional support remains a cornerstone in the management of ESCC and has been shown to ameliorate patients’ tolerance of treatment, quality of life, and long-term outcomes. The combination of ESCC and T2DM may present great challenges to patients in a multitude of nutrition-related areas. Severe weight loss, which may result from dysphagia, cancer-related cachexia, and/or uncontrolled diabetes mellitus, is a prognostic factor in patients with ESCC [32]. Based on these considerations, a logical and plausible interpretation of our findings was that severe weight loss may mask the negative prognostic effect of T2DM in patients with ESCC.

Despite showing the impact of T2DM on the prognosis of ESCC patients, the present study had several limitations. First, our study was a retrospective study, and the number of patients was relatively small, particularly in subgroup analyses, which increases the likelihood of spurious associations. Second, this study did not evaluate the usage of anti-diabetic drugs and the frequency of consultations because of incomplete clinical data. Therefore, additional investigations, especially multi-center prospective randomized controlled trials with adequate

| Characteristic | Univariate analysis | Multivariate analysis |
|---------------|---------------------|----------------------|
|               | HR 95% CI | P value | HR 95% CI | P value |
| Age (years)   |   |   |   |   |   |
| ≤45 vs. 46–59 vs. ≥60 | 1.002 0.990–1.015 0.720 | – – – | – – – | – – – |
| Sex           |   |   |   |   |   |
| Female vs. male | 0.769 0.607–0.975 0.030 | 0.865 0.680–1.101 0.239 | – – – | – – – |
| Smoking status|   |   |   |   |   |
| Yes vs. no    | 1.176 0.944–1.465 0.149 | – – – | – – – | – – – |
| Drinking status|   |   |   |   |   |
| Yes vs. no    | 1.195 0.922–1.548 0.178 | – – – | – – – | – – – |
| Weight loss rate|   |   |   |   |   |
| 0 vs. >0% to ≤5.0% vs. >5.0% to ≤10.0% vs. >10.0% | 1.168 1.047–1.302 0.005 | 1.118 1.000–1.251 0.060 | – – – | – – – |
| BMI (kg/m²)   |   |   |   |   |   |
| <18.5 vs. >18.5 to <25.0 vs. ≥25.0 | 0.970 0.779–1.207 0.784 | – – – | – – – | – – – |
| Tumor location|   |   |   |   |   |
| Upper vs. middle vs. lower | 0.932 0.767–1.134 0.483 | – – – | – – – | – – – |
| Tumor grade   |   |   |   |   |   |
| G1 vs. G2 vs. G3 | 1.489 1.271–1.745 <0.001 | 1.373 1.164–1.621 <0.001 | – – – | – – – |
| pT category   |   |   |   |   |   |
| T1 vs. T2 vs. T3 vs. T4 | 1.642 1.308–2.062 <0.001 | 1.257 0.982–1.611 0.070 | – – – | – – – |
| pN category   |   |   |   |   |   |
| N0 vs. N1 vs. N2 vs. N3 | 1.820 1.594–2.079 <0.001 | 1.474 1.181–1.839 0.001 | – – – | – – – |
| pTNM stage    |   |   |   |   |   |
| Stage I vs. stage II vs. stage III | 2.270 1.832–2.813 <0.001 | 1.237 0.872–1.754 0.233 | – – – | – – – |
| Complications |   |   |   |   |   |
| None vs. anastomotic leakage vs. pneumonia vs. others | 1.118 0.961–1.299 0.148 | – – – | – – – | – – – |
| T2DM          |   |   |   |   |   |
| With T2DM vs. without T2DM | 0.896 0.719–1.116 0.326 | – – – | – – – | – – – |

ESCC esophageal squamous cell carcinoma, BMI body mass index, T2DM type 2 diabetes mellitus, pT pathological tumor, pN pathological node, pTNM stage pathological tumor/node/metastasis, HR hazard ratio, 95% CI 95% confidence interval, – no comparison
statistical power are required to determine whether and how T2DM affects the survival of patients with ESCC.

Conclusions
Type 2 diabetes mellitus was not found to be an independent prognostic factor of OS in patients with ESCC. However, the combination of T2DM and severe weight loss may be used as a predictor of poor prognosis.

Abbreviations
BMI: body mass index; EC: esophageal cancer; ESCC: esophageal squamous cell cancer; HR: hazard ratio; T2DM: type 2 diabetes mellitus; OS: overall survival; pt: pathological tumor; pT: pathological node; pTNM: pathological tumor/node/metastasis; 95% CI: 95% confidence interval; CT: computed tomography; ROC: receiver operating characteristic.

Authors’ contributions
Contributions: (I) conception and design: WY, JHH; (II) administrative support: ZHZ, JPL; (III) provision of study materials or patients: WY, YQM; (IV) collection and assembly of data: WY, MIL; (V) data analysis and interpretation: WY, WZF. All authors read and approved the final manuscript.

Author details
1 Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China. 2 Department of Interventional Oncology, The First Affiliated Hospital, Sun Yat-sen University, No. 58, Zhongshan Second Road, Guangzhou 510080, Guangdong, P. R. China. 3 Department of Thoracic Surgery, Second Hospital of Lanzhou University, Lanzhou 730030, Gansu, P. R. China. 4 Department of Radiology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou 510060, Guangdong, P. R. China.

Acknowledgements
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.

Consent publication
Not applicable.

Ethics approval and consent to participate
The study was approved by Ethics Committee of the Sun-Yat Sen University, Guangzhou and Lanzhou University, Lanzhou.

Funding
There is not any funding for supporting this study.

Received: 12 September 2017 Accepted: 14 March 2018
Published online: 27 April 2018

References
1. Chen W, Zheng R, Zeng H, Zhang S. The incidence and mortality of major cancers in china, 2012. Chin J Cancer. 2016;35(1):73.
2. Malhotra G, Yanala U, Ravigatti A, Follert M, Vijayakumar M, Are C. Global trends in esophageal cancer. J Surg Oncol. 2017;115(5):564–79.
3. Wu CC, Chen CJ. Esophageal carcinoma. N Engl J Med. 2015;372(15):1472.
4. Maffi P, Scenici A. The burden of diabetes: emerging data. Dev Ophthalmol. 2017;60:1–5.
5. Singh S, Singh PP, Singh AG, Murad MH, McWilliams RR, Chan ST. Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Am J Gastroenterol. 2013;108(4):510–9.
6. Wang C, Wang X, Gong G, Ben Q, Qiu W, Chen Y, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer. 2012;130(7):1639–48.
7. Shau WY, Shao YY, Yeh YC, Lin ZZ, Kuo R, Hsu CH, et al. Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma. Oncologist. 2012;17(6):856–62.
8. Jiang Y, Ben Q, Shen H, Lu W, Zhang Y, Zhu J. Diabetes mellitus and incidence and mortality of colorectal cancer: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol. 2011;26(11):863–76.
9. Ge Z, Ben Q, Qian J, Wang Y, Li Y. Diabetes mellitus and risk of gastric cancer: a systematic review and meta-analysis of observational studies. Eur J Gastroenterol Hepatol. 2011;23(12):1127–35.
10. Larson SC, Wolk A. Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies. Diabetologia. 2011;54(5):1013–8.
11. Xu H, Jiang HW, Ding GX, Zhang H, Zheng LM, Mao SH, et al. Diabetes mellitus and prostate cancer risk of different grade or stage: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2013;99(3):241–9.
12. Hatlen P, Gronberg BH, Langhammer A, Carlsten SM, Amundsen T. Prolonged survival in lung cancer patients with diabetes mellitus. J Thorac Oncol. 2011;6(11):1810–7.
13. Vartotto J, Medford-Davis LN, Recht A, Flickinger J, Schaef er E, Shelby J, et al. Confirmation of the role of diabetes in the local recurrence of surgically resected non-small cell lung cancer. Lung Cancer. 2012;75(3):381–90.
14. Henniminki K, Li X, Sundquist J, Sundquist K. Risk of cancer following hospitalization for type 2 diabetes. Oncologist. 2010;15(6):548–55.
15. Bosetti C, Rosato V, Poliseli J, Levi F, Talaman R, Montella M, et al. Diabetes mellitus and cancer risk in a network of case-control studies. Nutr Cancer. 2012;64(5):643–51.
16. Huang W, Ben H, Ben Q, Cai Q, Zhu W, Li Z. Risk of esophageal cancer in diabetes mellitus: a meta-analysis of observational studies. Cancer Causes Control. 2012;23(2):263–72.
17. American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care. 2015;38(Suppl1):S8–16.
18. Zhan X, Guo X, Liu R, Hu W, Zhang L, Xiang N. Intervention using a novel biodegradable hollow stent containing polyactic acid-polyprolactone-polyethylene glycol complexes against lacrimal duct obstruction disease. PLoS ONE. 2017;12(6):e0178679.
19. Giovannucci E, Harlan DM, Archer MC, Bergensal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33(7):1674–85.
20. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4(8):579–91.
21. Cronin-Fenton DR, Murray LI, Whiteman DC, Cardwell C, Webb PM, Jordan SJ, et al. Reproductive and sex hormonal factors and oesophageal and gastric junction adenocarcinoma: a pooled analysis. Eur J Cancer. 2010;46(11):2067–76.
22. Klubo-Gwiezdzinska J, Costello J Jr, Patel A, Bauer A, Jensen K, Mete M, et al. Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer. J Clin Endocrinol Metab. 2013;98(8):3269–79.
23. Spellane S, Bennett K, Sharp L, Barron TI. A cohort study of metformin exposure and survival in patients with stage I–III colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2013;22(8):1364–73.
24. Sandulache VC, Hamblin JS, Skinner HD, Kubik MW, Myers JN, Zevallos JP. Association between metformin use and improved survival in patients with laryngeal squamous cell carcinoma. Head Neck. 2014;36(7):1039–43.
25. Cereto M, Tichet M, Abbie P, Oharma N, Lehmkuhl A, Rouaud F, et al. Metformin blocks melanoma invasion and metastasis development in ampk/p53-independent manner. Mol Cancer Ther. 2013;12(7):1605–15.
26. Karnevi E, Said K, Andersson R, Rosendahl AH. Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells. BMC Cancer. 2013;13:235.
27. Wu AH, Tseng CC, Bernstein L. Hiatal hernia, reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma. Cancer. 2003;98(5):940–8.
28. Samsom M, Vermeijden J, Smout A, Van D, Roelofs J, Van DP, et al. Prevalence of delayed gastric emptying in diabetic patients and relationship to dyspeptic symptoms: a prospective study in unselected diabetic patients. Diabetes Care. 2003;26(11):3116–22.
29. Zhen F, Shi S, Xue L, Liu J, Luo J. Study on the association of gastric conduit width and postoperative early delayed gastric emptying in middle-lower esophageal cancer patients undergoing Ivor-Lewis procedure. Zhonghua Wei Chang Wai Ke Za Zhi. 2016;19(9):985–9.
30. Nayak BS, Butcher DM, Bujhawan S, Chang D, Chang S, Cabral-Samaroo D, et al. Association of low serum creatinine, abnormal lipid profile, gender, age and ethnicity with type 2 diabetes mellitus in Trinidad and Tobago. Diabetes Res Clin Pract. 2011;91(3):342–7.
31. Golightly LK, Jones MA, Hamamura DH, Stolpman NM, McDermott MT. Management of diabetes mellitus in hospitalized patients: efficiency and effectiveness of sliding-scale insulin therapy. Pharmacotherapy. 2006;26(10):1421–32.
32. Miller KR, Bozeman MC. Nutrition therapy issues in esophageal cancer. Curr Gastroenterol Rep. 2012;14(4):356–66.